🇺🇸 FDA
Company

Aptevo

Aptevo Therapeutics

APVO pharma USA

Quick answer

Aptevo is a pharma company (APVO) headquartered in SEATTLE, WA, USA with 9 tracked pipeline programs.

Pipeline (9)

project

ALG.APV-527

Solid Tumor

Phase 2 · small_molecule · active

1 trials project

TRU-016 and bendamustine

Chronic Lymphocytic Leukemia (CLL)

Phase 2 · small_molecule · completed

1 trials project

20 mg/kg TRU-016 + Rituximab

Chronic Lymphocytic Leukemia

Phase 1 · mab · terminated

1 trials project

APVO210

Psoriasis

Phase 1 · mab · terminated

1 trials project

APVO436

AML

Phase 1 · mab · active

2 trials project

APVO436

Acute Myeloid Leukemia (AML)

Phase 1 · small_molecule · active

1 trials project

ES414

Prostate Cancer

Phase 1 · mab · completed

1 trials project

TRU-016

B-cell Small Lymphocytic Lymphoma Recurrent

Phase 1 · small_molecule · completed

1 trials project

TRU-016 (anti-CD37 protein therapeutic)

Chronic Lymphocytic Leukemia (CLL)

Phase 1 · small_molecule · completed

1 trials

Patents (8)

patent

US 11939392

CD123 binding proteins and related compositions and methods

Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11725060

Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and m

Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11352426

CD3 binding polypeptides

Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11312786

Oncofetal antigen binding proteins and related compositions and methods

Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11242400

CD123 binding proteins and related compositions and methods

Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10676533

Methods of treatment of CD123 overexpressing disorders

Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10307481

CD37 immunotherapeutics and uses thereof

Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10239949

Oncofetal antigen binding proteins and related compositions and methods

Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)